Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

DermTech Yönetim

Yönetim kriter kontrolleri 2/4

DermTech's CEO'su Bret Christensen, May2023 tarihinde atandı, in görev süresi 1.42 yıldır. in toplam yıllık tazminatı $ 1.93M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.2% maaş ve 79.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.007% ine doğrudan sahiptir ve bu hisseler $ 50.00 değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 3 yıldır.

Anahtar bilgiler

Bret Christensen

İcra Kurulu Başkanı

US$1.9m

Toplam tazminat

CEO maaş yüzdesi	20.2%
CEO görev süresi	1.4yrs
CEO sahipliği	0.007%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	3yrs

Son yönetim güncellemeleri

Recent updates

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

May 21

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Mar 02

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

May 10

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

May 06

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Nov 08

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Oct 11

DermTech grants stock options

Oct 11

Diving Into DermTech

Sep 01

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Aug 10

DermTech: Approaching An All Or Nothing Moment

Jun 13

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 04

DermTech - Taking A Second Look At The Growth Thesis

Mar 31

DermTech: Adoption Headwinds And Earnings Misses

Dec 23

Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Dec 02

CEO Tazminat Analizi

Bret Christensen'un ücretlendirmesi DermTech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	-US$90m
Dec 31 2023	US$2m	US$389k	-US$101m

Tazminat ve Piyasa: Bret 'nin toplam tazminatı ($USD 1.93M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Bret şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Bret Christensen (53 yo)

1.4yrs

Görev süresi

US$1,928,967

Tazminat

Mr. Bret Christensen serves as Chief Executive Officer, President and Director at DermTech, Inc. since May 08, 2023. He serves as Director of Axena Health, Inc. Mr. Christensen had been Chief Commercial Of...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bret Christensen	President	1.4yrs	US$1.93m	0.0071% $ 50.0
Kevin Sun	CFO, Treasurer & Secretary	5.1yrs	US$934.85k	0.57% $ 4.0k
Ray Akhavan	General Counsel	3.8yrs	US$818.76k	0.19% $ 1.3k
Steve Kunszabo	Senior Director of Investor Relations	no data	Veri yok	Veri yok
Jennifer Eilemberg	Chief Compliance Officer	2.3yrs	Veri yok	Veri yok
Loren Clarke	Chief Medical Officer	3.3yrs	Veri yok	Veri yok
Mark Aguillard	Chief Commercial Officer	1.1yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: DMTK.Q 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bret Christensen	President	1.4yrs	US$1.93m	0.0071% $ 50.0
Herman Rosenman	Independent Director	5.2yrs	US$149.64k	0.28% $ 2.0k
Kirk Malloy	Independent Director	2.3yrs	US$136.64k	0.094% $ 661.8
Matthew Posard	Independent Chairman of the Board	8.3yrs	US$188.64k	0.35% $ 2.5k
Mark Capone	Independent Director	2.3yrs	US$139.64k	0.081% $ 573.7
Cynthia Collins	Independent Director	5.2yrs	US$156.64k	0.20% $ 1.4k
Nathalie Keraudy	Independent Director	3yrs	US$134.64k	0.092% $ 649.5

3.0yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DMTK.Q 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3 yıldır).

DermTech Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces Change of CEO

High number of new directors

DermTech, Inc. Announces Board Committee Appointments

Recent updates

DermTech, Inc.(NasdaqCM:DMTK) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of DermTech

Motion for Joint Administration Filed by DermTech, Inc.

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

First quarter 2024 earnings released: US$0.58 loss per share (vs US$1.02 loss in 1Q 2023)

Price target decreased by 26% to US$2.04

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 11% to US$3.20

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Consensus EPS estimates upgraded to US$3.11 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Consensus revenue estimates fall by 16%

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

DermTech, Inc. Announces Change of CEO

Price target decreased by 22% to US$5.75

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 11% to US$7.00

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

Price target decreased to US$7.33

High number of new directors

DermTech, Inc. Announces Board Committee Appointments

Consensus forecasts updated

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

DermTech grants stock options

Diving Into DermTech

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Dermtech Announces New Board Appointment

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

DermTech: Approaching An All Or Nothing Moment

President exercised options to buy US$59k worth of stock.

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

High number of new and inexperienced directors

DermTech, Inc. Presents New Research Differentiating Atopic Dermatitis and Psoriasis At the Society for Investigative Dermatology's Annual Meeting

DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022

DermTech, Inc., Annual General Meeting, May 26, 2022

DermTech - Taking A Second Look At The Growth Thesis